{"id":"W4389247985","doi":"10.1182/blood-2023-177567","title":"Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with Fixed-Dose Venetoclax Plus Rituximab","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Incyte; BeiGene; F. Hoffmann-La Roche; TG Therapeutics; Gilead Sciences; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Venetoclax; Internal medicine; Bendamustine; Regimen; Progression-free survival; Rituximab; Randomized controlled trial; Oncology; Chronic lymphocytic leukemia; Surgery; Leukemia; Chemotherapy; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003681607,0.0005376317,0.001408123,0.0001643446,0.0002320647,0.0007522373,0.000582843,0.0008007002,0.001811111],"category_scores_gemma":[0.002109078,0.0002560543,0.001156643,0.0002038565,0.0005115433,0.0004838332,0.0005330571,0.001917025,0.000200963],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006364575,"about_ca_system_score_gemma":0.0006073383,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004582836,"about_ca_topic_score_gemma":0.001498761,"domain_scores_codex":[0.9988955,0.0007514943,0.00004599809,0.0001517142,0.00005622469,0.00009912579],"domain_scores_gemma":[0.9982424,0.0005249772,0.0006353107,0.000158722,0.00005073547,0.0003879182],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9504926,0.00264856,0.01859164,0.0004124207,0.001484696,0.00006283935,0.0001101462,0.0007614036,0.002855435,0.0001736797,0.001014354,0.02139212],"study_design_scores_gemma":[0.5922694,0.2761992,0.1170058,0.0002210831,0.003717608,0.0004460936,0.0001329017,0.003057348,0.001749506,0.0005819928,0.00456082,0.00005827201],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961299,0.002284383,0.00007508246,0.0001614807,0.00005811026,0.0001580975,0.0001910512,0.00001023413,0.0009316998],"genre_scores_gemma":[0.9972907,0.0005142444,0.0002145882,0.0002832678,0.0001387699,0.0002887063,0.0005593005,0.000003743963,0.0007067719],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003681607,"threshold_uncertainty_score":0.01947039,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0141538266993218,"score_gpt":0.2723629041360706,"score_spread":0.2582090774367488,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}